Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant

A major advance was made to reduce the side effects of cancer therapy via the elucidation of the tumor-specific lytic path “hyperploid progression-mediated death” targeting retinoblastoma (Rb) or p53-mutants defective in G1 DNA damage checkpoint. The genetic basis of human cancers was uncovered thro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Frank-Un, Castro, Miguel, Linse, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Frontier
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701912/
https://www.ncbi.nlm.nih.gov/pubmed/33312882
http://dx.doi.org/10.5306/wjco.v11.i11.854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7701912/
https://www.ncbi.nlm.nih.gov/pubmed/33312882
http://dx.doi.org/10.5306/wjco.v11.i11.854

Ejemplares similares